Drugs / SMET12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06208033 | Jan → Oct 2024 | non-small cell lung carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMET12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06208033 ↗ |
| Route | Intravenous | “SMET12: IV，60μg，Q2W，injected the day after toripalimab” NCT06208033 ↗ |